Skip to main content

Sage Therapeutics slumps as Biogen deal may dampen M&A hopes

Weakness in shares of Sage Therapeutics may be related to news that Biogen and Ionis Pharmaceuticals have expanded their strategic collaboration through a new ten-year collaboration agreement.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.